Citi Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

Citi analyst David Lebowitz reiterated a Buy rating and $382.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).

The analyst comments "At the European Association for the Study of the Liver (EASL) Congress, Madrigal presented new analyses from its ongoing Ph3 MAESTRO-NASH trial for Rezdiffra. Specifically, Madrigal presented an AI-driven assessment of fibrosis called qFibrosis (Histoindex) that indentified 30 fibrotic features on NASH biopsies that may be predictive of progression to cirrhosis and decompensated cirrhosis. In MAESTRO-NASH, total qFibrosis score showed significant fibrosis improvement and less progression of fibrosis for patients treated with Rezdiffra than placebo. Madrigal also presented noninvasive test data through 3 years that demonstrated 91% of Rezdiffra-treated patients achieved improvement or stabilization of liver stiffness, suggesting durable treatment response."

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $235.97 yesterday.

You May Also Be Interested In

• Madrigal Pharmaceuticals adds J&J executive to its board
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'